BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22406588)

  • 1. Resectable pancreatic cancer: is surgery the best first step?
    Russo S; Chabot J; Saif MW
    JOP; 2012 Mar; 13(2):151-4. PubMed ID: 22406588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant strategies for resectable pancreatic cancer: have we made progress?
    Russo S; Jain AK; Saif MW
    JOP; 2012 Mar; 13(2):139-42. PubMed ID: 22406585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of borderline resectable pancreatic adenocarcinoma.
    Jia Y; Wang TJ; Allendorf J; Saif MW
    JOP; 2012 Mar; 13(2):147-50. PubMed ID: 22406587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locally advanced pancreatic adenocarcinoma: update and progress.
    Ng J; Zhang C; Gidea-Addeo D; Saif MW
    JOP; 2012 Mar; 13(2):155-8. PubMed ID: 22406589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in the management of borderline resectable pancreatic cancer.
    Sharma J; Ng J; Goodman MD; Saif MW
    JOP; 2013 Mar; 14(2):123-5. PubMed ID: 23474551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment for resectable pancreatic cancer.
    Chua YJ; Cunningham D
    J Clin Oncol; 2005 Jul; 23(20):4532-7. PubMed ID: 16002844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Sharma C; Horowitz D; Chabot J; Saif MW
    JOP; 2011 Jul; 12(4):343-6. PubMed ID: 21737892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.
    Stessin AM; Meyer JE; Sherr DL
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1128-33. PubMed ID: 18538501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma.
    Yang R; Cheung MC; Byrne MM; Jin X; Montero AJ; Jones C; Koniaris LG
    Arch Surg; 2010 Jan; 145(1):49-56. PubMed ID: 20083754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenocarcinoma of the pancreas: the rationale for neoadjuvant therapy.
    Sperti C; Pasquali C; Pastorelli D; Ferronato A; Decet G; Pedrazzoli S
    Acta Biomed; 2003; 74 Suppl 2():91-5. PubMed ID: 15055044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
    Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
    Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
    Morak MJ; van der Gaast A; Incrocci L; van Dekken H; Hermans JJ; Jeekel J; Hop WC; Kazemier G; van Eijck CH
    Ann Surg; 2008 Dec; 248(6):1031-41. PubMed ID: 19092348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
    Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
    Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
    Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for pancreatic cancer: a review.
    Zuckerman DS; Ryan DP
    Cancer; 2008 Jan; 112(2):243-9. PubMed ID: 18050292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.
    Sutton JM; Abbott DE
    World J Gastroenterol; 2014 Nov; 20(42):15564-79. PubMed ID: 25400440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy for resectable pancreatic cancer.
    Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
    Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.